CardioExchange Archive

March 17th, 2014

Selections from Richard Lehman’s Literature Review: March 17th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include a comparison of the safety and efficacy of the new oral anticoagulants with warfarin in patients with AF, a study on mortality from ruptured abdominal aortic aneurysms, and more.

---

September 25th, 2013

Is It Safe to Treat Acute Pulmonary Embolism in an Outpatient Setting?

Christopher Kabrhel, MD MPH

Christopher Kabrhel discusses his research group’s study of the factors associated with clinical deterioration and the need for hospital-based interventions after an acute pulmonary embolism.

---

September 18th, 2013

Is Edoxaban the Most Promising of the Novel Anticoagulants?

Samuel Goldhaber, MD

Samuel Z. Goldhaber offers his perspective on the Hokusai-VTE randomized trial comparing edoxaban and warfarin in patients with symptomatic venous thromboembolism.

---

August 12th, 2013

Selections from Richard Lehman’s Literature Review: August 12th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include BP targeting in patients with recent lacunar stroke, intermittent pneumatic compression for reducing DVT risk in patients who’ve had a stroke, and more.

---

July 1st, 2013

New Anticoagulant Found Safe and Effective in Acute Venous Thromboembolism

Larry Husten, PHD

In a large clinical trial the new oral anticoagulant apixaban (Eliquis, Pfizer and Bristol-Myers Squibb) was at least as effective as standard therapy and caused fewer bleeding complications in patients with acute venous thromboembolism (VTE). The results of the AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy) trial are being presented today at […]

---

December 8th, 2012

Prolonged Anticoagulation with Apixaban Beneficial in Venous Thromboembolism

Larry Husten, PHD

A new study suggests that extending anticoagulant therapy for an additional year may be beneficial after patients with venous thromboembolism complete their initial course of therapy. The results of AMPLIFY-EXT (Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-Line Therapy-Extended Treatment) were presented at the annual meeting of the American Society […]

---